440 Activity and safety of camrelizumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced non-small-cell lung cancer

by Wei Wang, Peng Gao, Lu Sun, Guo Gui Sun, Jing Hao Jia, Xue Min Yao, Ming Da Chen, Wei Nan Yao
Published 2020-11-01